Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-105
- Development stage
- Preclinical
- Lead developer
- Dewcell Biotherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
DCB-105 is an engineered artificial platelet cell therapy under development by Dewcell Biotherapeutics for the treatment of inherited platelet dysfunction (inherited thrombocytopenia). The therapy is developed using Dewcell's proprietary platform, which differentiates stem cells into megakaryocytes and optimizes them for scalable, GMP-compliant artificial platelet production. DCB-105 is currently in the discovery/preclinical stage of development.
- Other names
- Inherited-TP
Beyond the preview
Go deeper on DCB-105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-105.